Showing results (1-10 of 205) with videos related to
Sort By:
Pageof 21
FEBS Letters|August 28, 1995
Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymeraseG Sutter, M Ohlmann, V ErfleMethods in Molecular Medicine|March 11, 2011
Recombinant Vaccinia Virus MVA for Generation and Analysis of T Cell Responses Against Tumor Associated AntigensI Drexler, K Heller, M Ohlmann, et al.Biotechniques|June 27, 2000
Transient host range selection for genetic engineering of modified vaccinia virus AnkaraC Staib, I Drexler, M Ohlmann, et al.The Journal of General Virology|February 24, 1998
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cellsI Drexler, K Heller, B Wahren, et al.Vaccine|April 3, 2001
Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat modelG Weidinger, M Ohlmann, B Schlereth, et al.Journal of Virological Methods|June 1, 1996
Heparin-binding capacity of the HIV-1 NEF-protein allows one-step purification and biochemical characterizationB Kohleisen, K Gaedigk-Nitschko, M Ohlmann, et al.AIDS (London, England)|December 22, 1999
Stable expression of HIV-1 Nef induces changes in growth properties and activation state of human astrocytesB Kohleisen, E Shumay, G Sutter, et al.Cancer Research|October 16, 1999
Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivoI Drexler, E Antunes, M Schmitz, et al.Cancer|March 30, 2000
Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirusV Valdez Graham, G Sutter, M V José, et al.Experimental Cell Research|June 1, 1984
Elimination of mycoplasmas from cell cultures and establishment of mycoplasma-free cell linesJ Schmidt, V ErflePageof 21